<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Islet Transplantation using one’s own Differentiated stem cells: A Review and Potential Applications

Lakey, Jonathan R. T. ; Jenkins, Ian ; Lernhardt, Waldemar ; Uffens, Jayson ; Alexander, Michael ; Mesples, Alejandro Daniel ; Abalovich, Adrián Gustavo ; Casazza, Krista ; Mutto, Adrián Angel Icon; Robinson, Bradley ; Lopez Vitolas, Ivan ; Gutiérrez Castrellón, Pedro ; Yang, Jan

Otros responsables

Fecha

01/2025

Editorial

BiomedGrid LLC

Revista

American Journal of Biomedical Sciences and research

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

2642-1747

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Resumen

Diabetes is one of the most common chronic diseases worldwide, with around 537 million adults aged 20-79 living with the disease. It is a global epidemic and has a rapidly rising incidence. Traditional treatments for diabetes have limited efficacy in achieving long-term disease control. In recent years, the autologous infusion of bone marrow-derived mononuclear cells (BMMNC) has become a novel and effective therapeutic approach in treating autoimmune type 1 diabetes (T1DM). BMMNC contains two important types of stem cells, bone marrow-derived hematopoietic stem cells (BMHSC) and bone marrow-derived mesenchymal stem cells (BMMSC), which are currently used independently or coordinately in the treatment of T1DM. In this review, we summarize the clinical data concerning BMMNC, BMHSC, and BMMSC infusion in patients with diabetes (including Type 1, Type 2, and secondary diabetes) and diabetes-related complications. Research suggests that the autologous infusion of bone marrow stem cells is safe and effective, offering the potential to be widely used in patients with diabetes.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by